Videos
The Differences Between CAR T-cell Therapy and Bispecific Monoclonal Antibodies
Myeloma expert Dr. Brian G.M. Durie discusses the main differences between the CAR T cells and bispecific monoclonal antibodies.
The BOTTOM LINE: Discuss with your doctor to…
Event
Each year, the San Fernando Valley Support Group comes together to support the International Myeloma Foundation in it's mission to improve the lives of multiple myeloma patients everywhere while working towards prevention and a cure.
Event
Allow me to introduce myself; my name is Jennifer Chanaca, and I'd like to elaborate on the significance of my mission. My grandmother's determination inspired this fundraiser. This cancer is not yet curable and I am motivated by her three-year fight and independence to find a cure. I'd like to use…
News Article
The International Myeloma Foundation Reached Over 41 Million in More Than 45 Countries During 2023 Myeloma Action Month!
What's your #MYelomaSTORY?
STUDIO CITY, Calif., April 06, 2023 -- At the conclusion of this year’s Myeloma Action Month (MAM), the International…
Videos
Tests to Monitor Patients on Maintenance Therapy
Myeloma expert Dr. Brian G.M. Durie discusses what tests are used when monitoring patients who are doing well on maintenance therapy and the importance of close monitoring.
The BOTTOM LINE: It is important…
News Article
PHILADELPHIA, April 03, 2023 -- The Annual Miles for Myeloma Hybrid 5K Run/Walk will once again “Redefine Being Together” on Saturday, April 29, virtually and in-person at FDR Park in Philadelphia, PA — with the common goal of finding a cure for multiple myeloma.
For the…
Videos
IMF Nurse Leadership Board member Beth Faiman Conducts a Special Q&A
In this special Myeloma ACTION Month Q&A, International Myeloma Foundation Nurse Leadership Board member Beth Faiman PhD, RN, MSN, APRN-BC, AOCN®, FAAN shares her myeloma story, discusses peripheral neuropathy, MRD…
Videos
In recent years, many new myeloma drugs have been developed and have greatly improved patients' lives. Patients need to know how each drug works so they can make informed decisions with their healthcare providers.
What to Expect
An explosion in drug development in myeloma over…
Videos
Understanding Functional High-Risk Myeloma
Myeloma expert Dr. Brian G.M. Durie discusses what it means when a patient is functionally high risk and what new therapies may benefit these patients.
The BOTTOM LINE: Emerging immune therapies, such as CAR-T…
Videos
Myeloma Patient Michael Tuohy and Care Partner and Spouse Robin Tuohy Share Their Story
In this animated video, Michael and Robin Tuohy tell the story of how they were inspired to help others facing multiple myeloma. Fueled by Michael's diagnosis, Robin, Michael, their kids, and their pets…
Videos
Dr. Joseph Mikhael Conducts a Special Q&A on Facebook
During March, Myeloma ACTION Month, IMF Chief Medical Officer Dr. Joseph Mikhael answered questions LIVE on Facebook and shared his own myeloma story.
Some of the questions addressed in this video include:
…
News Article
Become a Multiple Myeloma Advocate Today
Help the IMF’s Advocacy program fight for myeloma progress
By Danielle Doheny, IMF Director, Public Policy & Advocacy
Advocacy is one of the International Myeloma Foundation’s four founding pillars, along with Research,…
Videos
Back in person for the first time since 2019, the International Myeloma Foundation (IMF) is excited to announce that the 2023 Boca Raton Patient and Family Seminar took place on March 17-18, 2023, in Boca Raton, Florida.
Meeting Slides
…
Page
Relapse of myeloma is defined as the reappearance of signs and symptoms after a period of improvement. Patients with relapsed disease have been treated, then developed signs and symptoms of myeloma at least 60 days after treatment ended.
*click on the rectangle button on the lower right…
News Article
Myeloma Survivors and Patient Advocates Attend the 2022 ASH Annual Meeting and Exposition
Leaders of myeloma support groups share their takeaways
By Robin Tuohy, IMF Vice President, Support Groups
Each December, the IMF brings a team of myeloma…
Event
Jennifer Chanaca competes in the Miss Connecticut Pageant and is using the pageant to raise myeloma awareness and funds.
Page
What Is a Care Partner?
A care partner stands alongside a person with multiple myeloma, helping with daily tasks and decisions. Unlike the word "caregiver," which can sound one-sided, "care partner" shows that both people are working together. The care partner might be a family member…
News Article
The Food and Drug Administration (FDA) has granted Priority Review for for elranatamab, an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody (BsAb), for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). The FDA’s decision on the…
Page
What Is Immunocytokine Therapy? Immunocytokine therapy is a type of immunotherapy that uses cytokines. Cytokines are small proteins our bodies make that help cells of our immune system communicate. Some cytokines increase the activity of the immune system, while others slow down or regulate…
Page
Chimeric Antigen Receptor T-cell Therapy (CAR T-cell Therapy)CAR T-cell therapy, also known as Adoptive Cellular Therapy (ACT), is a type of individualized immunotherapy. In CAR T-cell therapy, some of your body’s own white blood cells, in this case T cells, are collected and sent to a lab. T cells…
Page
How Bispecific Antibodies WorkYour T cells are powerful soldiers of the immune system, but they aren't always able to recognize and attack myeloma cells on their own. Bispecific antibodies act as a connector bridge. One "arm" of the bispecific antibody binds to a specific protein, or antigen, on…
Page
As research advances, individuals affected by multiple myeloma are being exposed to emerging cancer therapies that show promise for furthering treatment. These therapies offer fresh options for those who have relapsed, become resistant to standard treatments, or are seeking the latest options in…
News Article
STUDIO CITY, CA — With the International Myeloma Foundation (IMF) at the forefront, Myeloma Action Month is held every year for the whole month of March to encourage individuals and groups to take actions that positively impact the myeloma community. This year the IMF…
Videos
Virtual Multiple Myeloma Community Workshop A virtual multiple myeloma workshop addressing the needs specific to communities in the Midwest region.The IMF Virtual Regional Community Workshop will include an introduction to myeloma, upfront treatments at diagnosis, maintenance therapy, relapse…
Page
What Is Aredia?
AREDIA® is a bisphosphonate medication that prevents bone damage in multiple myeloma patients. Normally, our body has a delicate balance between cells that build bone (osteoblasts) and cells that break down bone (osteoclasts). For myeloma patients, signals sent by cancerous…
News Article
In February 2023, a new report documenting for the first time the prevalence (occurrence) of smoldering myeloma (SMM) in a screened population was published in the prestigious monthly journal Nature Medicine
This report is very important for both the iStopMM project and the…
Videos
Dr. Sebastian Grosicki, Medical University of Silesia, presents the results of the MagnetisMM-5 study a phase 3, multicenter, randomized, open-label trial designed to assess the efficacy and safety of elranatamab monotherapy or in combination with daratumumab in relapsed refractory multiple myeloma…
Videos
How the IMF Is Changing the Course of Myeloma in the African American Community
The M-Power project is partnering with cities across the country to turn the core vision of the International Myeloma Foundation's Diversity Initiative into a reality; improving the short- and long-term outcomes of…
News Article
Volunteer Opportunity: National Cancer Institute
Volunteers Sought to Share Myeloma Patient Experience: The NCI’s Advocacy Relations Department reached out to the IMF for help. They are seeking individuals with a connection to myeloma to utilize their experiences to help the NCI…
Videos
Dr. Evangelos Terpos, National and Kapodistrian University of Athens, presents an abstract on increased baseline circulating tumor cells levels in patients with newly-diagnosed multiple myeloma and its association with poor prognosis.
Background:
The presence of circulating tumor cells (CTCs…
Videos
Dr. Efstathios Kastritis, National and Kapodistrian University of Athens, presents a summary real world evidence for the efficacy and clinical use of selinexor combinations, as well as the post-progression therapies and their outcome
Background:
Selinexor is the first in class, orally…
Videos
Dr. Suzanne Trudel, Princess Margaret Cancer Centre, discusses the results of a tocilizumab (TCZ) pretreatment arm of the ongoing Phase I study of cevostamab (an FcRH5xCD3 TDB) to see if a single dose of TCZ prior to cevostamab reduces the incidence of cytokine release syndrome.
Background:…
Videos
Dr. Shaji Kumar from Mayo Clinic presents the results of the ASCENT trial, which studied fixed-duration therapy with Daratumumab, Carfilzomib, and Dexamethasone for high-risk smoldering multiple myeloma.
Background:
The optimal approach for high-risk Smoldering Multiple Myeloma patients is…
News Article
Holiday Concert Fundraiser a Success!
The Christmas in the City fundraiser was held on Monday, December 12th, 2022, at the Pantages Theatre in Minneapolis. The one-night-only holiday concert raised a total of $5,605 for multiple myeloma research at the International Myeloma Foundation (…
News Article
On Monday, January 30, the Associated Press (AP) reported that President Joe Biden will end two national emergencies addressing COVID-19 on May 11. …
Page
What Is Zometa?
Zometa® (zoledronic acid) is a medication known as a bisphosphonate that prevents bone damage in multiple myeloma patients. Our body closely controls cells that build bone (osteoblasts) and cells that break down bone (osteoclasts). For myeloma patients, signals sent by myeloma…
Videos
Dr. Sandy Wong, University of California San Francisco, presents the long-term follow-up data for intravenous ALNUC and preliminary data for subcutaneous ALNUC in patients with relapsed or refractory multiple myeloma from the phase 1 study.
Background:
Patients with multiple myeloma who…
News Article
(The speaker line-up for this event was updated on February 6, 2023.)
BOCA RATON, Fla., Feb. 02, 2023 — The International Myeloma Foundation (IMF) today announced that this year’s first Patient and Family Seminar is taking place in-person on March 17–18…
Videos
Is Using CAR T-cell Therapy as a Frontline Treatment Option Effective?
Myeloma expert Dr. Brian G.M. Durie discusses results from the FasTCAR-T study reported at ASH 2022.
The BOTTOM LINE: Using CAR T-cell therapy as a frontline treatment is shown to be…
Videos
IMF Chief Medical Officer Dr. Joseph Mikhael discusses the top Multiple Myeloma Abstracts presented at ASH 2022
Videos
IMF Chief Medical Officer Dr. Joseph Mikhael discussed the latest research on these healthcare disparities as they were reported on during the 2022 American Society of Hematology annual conference.
For more information about the IMF's diversity program please visit the M-POWER project website:…
Videos
Virtual Multiple Myeloma Community Workshop A virtual multiple myeloma workshop addressing the needs specific to communities in the Northeast and Southern region.The IMF Virtual Regional Community Workshop will include an introduction to myeloma, upfront treatments at diagnosis, maintenance…
Videos
MGUS Cases with Multiple Paraproteins
Dr. Sæmundur Rögnvaldsson presents the results of the first large and prospective examination of MGUS cases with multiple paraproteins.
Abstract title:
Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results…
Videos
Results of Phase 1 CAR T-cell Therapy Study
Dr. Jesus Berdeja presents a study on the interim results from the dose-escalation phase (Part A) of CC-95266-MM-001 (NCT04674813), a phase 1 study evaluating BMS-986393 (CC-95266), an autologous CAR T-cell therapy targeting GPRC5D in R/R MM patients…
Videos
MagnetisMM-3 Results: Elranatamab in Relapsed Myeloma
Dr. Nizar Bahlis presents the results of the ongoing MagnetisMM-3 clinical trial looking at the effects of elranatamab in people with multiple myeloma whose cancer did not respond to treatment at all or came back after responding to…
Videos
The Results of MagnetisMM-1: Elranatamab on Relapsed Myeloma
Dr. Noopur Raje presents the results of MagnetisMM-1 the first-in-human study evaluating the safety, pharmacokinetics, pharmacodynamics, and efficacy of elranatamab for patients with relapsed or refractory multiple myeloma.
Abstract…
Videos
Impact of Location, Age, Socio-Economic Status, and Race on Myeloma Outcomes
Dr. Ashley Rosko presents a study to determine the combined impact of location, age, socio-economic status, and race on transplant access and overall survival.
Abstract title:
Multiple Myeloma Transplant:…
News Article
Imagine being served up content that met you where you are in your patient journey. You visit the IMF website and learn what clinical trials you qualify for, or which myeloma experts can best help you in your region. To better serve its patient community, the International Myeloma Foundation (IMF)…